BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26595825)

  • 1. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function.
    Botero Aguirre JP; Restrepo Hamid AM
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010481. PubMed ID: 26595825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating progressive disseminated histoplasmosis in people living with HIV.
    Murray M; Hine P
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD013594. PubMed ID: 32343003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.
    Blyth CC; Hale K; Palasanthiran P; O'Brien T; Bennett MH
    Cochrane Database Syst Rev; 2010 Feb; 2010(2):CD006343. PubMed ID: 20166083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
    Cortegiani A; Russotto V; Maggiore A; Attanasio M; Naro AR; Raineri SM; Giarratano A
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD004920. PubMed ID: 26772902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
    Hamill RJ; Sobel JD; El-Sadr W; Johnson PC; Graybill JR; Javaly K; Barker DE
    Clin Infect Dis; 2010 Jul; 51(2):225-32. PubMed ID: 20536366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.
    Falagas ME; Karageorgopoulos DE; Tansarli GS
    PLoS One; 2013; 8(10):e77075. PubMed ID: 24204739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.
    Bes DF; Rosanova MT; Sberna N; Arrizurieta E
    Pediatr Infect Dis J; 2014 Aug; 33(8):e198-206. PubMed ID: 24618932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of nephrotoxicity associated with amphotericin B deoxycholate.
    Johnson JR
    Clin Infect Dis; 2004 Jan; 38(2):303; author reply 306-7. PubMed ID: 14699469
    [No Abstract]   [Full Text] [Related]  

  • 16. Voriconazole versus amphotericin B in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Johansen HK
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B formulations: a comparative review of efficacy and toxicity.
    Hamill RJ
    Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia.
    Johansen HK; Gøtzsche PC
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD000969. PubMed ID: 25188673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis.
    Tsekoura M; Ioannidou M; Pana ZD; Haidich AB; Antachopoulos C; Iosifidis E; Kolios G; Roilides E
    Pediatr Infect Dis J; 2019 Jan; 38(1):42-49. PubMed ID: 29596219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral antifungal medication for toenail onychomycosis.
    Kreijkamp-Kaspers S; Hawke K; Guo L; Kerin G; Bell-Syer SE; Magin P; Bell-Syer SV; van Driel ML
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD010031. PubMed ID: 28707751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.